ABSTRACT
Introduction
The experience to classify elastin turnover changes and elastin degradation in hypertensive patients in particular is one of the first steps to look for immunological instead of instrumental criteria for the changes. Do these immunological indices change under medicinal control of arterial tension? Are there any relations between AT values and those of immunological indices typical for elastin degradation ? These are issues motivating the executed survey.
To study the dynamics of elastin degradation indices in treated hypertensive persons in connection with antihypertensive therapy carried out in the course of two years.
Materials and Methods
From a group of patients having newlystated moderate arterial hypertension 80 accepted to participate in our survey and were divided into two groups each comprised by 40 persons. Monotherapy with ACE-inhibitor (group A) and with Bblocker (group B) was appointed. Patients' selection was considered with their compliance and with the initial heart frequency registered in ECG and with the cardio-indications known for both medicines.
As the anti-hypertensive effect and medicine tolerance had to be recorded control check-ups were carried out on the tenth day and monthly till the end of the second year, starting from of treatment start. On the sixth month, at the end of the first year and at the end of the second year of the treatment, beside AT control were executed a blood sugar test, lipid profile and ECG. On the sixth month, at the end of the first year and at the end of the second year of the treatment were executed tests of elastin and collagen turnover immunological indices.
B-blocker administered to the patients was Atenolol (Sopharma) with a dosage of 50-100 mg and was taken twice daily.
Selection of Atenolol was made due to the following considerations: -This medicine has a well known antihypertensive effect in the clinical practice. -Its effect on small and big arterial vessels elasticity is examined. Its effect on pulse wave, respectively on arterial stiffness, is already described and known in several studies (3, 4, 8, 16 ). -The expected protective effect on vessels' elastin structures. The ACE-inhibitor applied in the second group of hypertensive persons is Trandolapril (Gopten of Knoll-About) taken in dosage 2-4 mg once a day.
Selection of Trandolapril was made due to the following considerations: -Favourable impact on small vessels' walls elasticity, described in experimental surveys (3, 4, 8, 16) ; -Expected favourable impact due to control over synthesis of one of the basic pathologic factors -angiotensin II (13, 15); -Antihypertensive impact of this medicine known in the clinical practice; -Prolonged activity and impact over tissue renin-angiotensin-aldosterene system (RAAS). Elastin immunological tests were carried out in "General Biology" Section of High Medical Institute -city of Pleven. The test methods are based on usage of immunolinking sorbent sample (ELISA) for determination of specific antibodies and degradation products in serum (1, 2, 5, 6,). The tested blood / 10 ml/ was taken from the tested persons during the morning hours (8 -9 .30 a.m.), twelve hours after their last food intake. After one-hour stay the blood is centrifuged at low revolutions; the separated serum is divided for triple test in chemically clean glass tubes, well closed and stored at -18°C.
Determination method for elastin-degradation peptides (EDP) was applied. It was developed in "Human Biology" Section (1, 4, 5,) . Polysterene plates were flushed with antihuman monoclonal antibodies against elastin /SIGMA,USA/ (10µg/ml) with 0.05 M carbonate buffer (pH-9.6); then they are incubated for three hours at 37°C and then 24 hours at 4°C. Follows washing with phosphate buffer 0.015 mol/l PBS containing 0.05% Tween-20 and 0.1% bovine serum albumen /BSA,SIGMA,USA/. 100 µl of human serum (diluted 1:5) is applied and then incubated for one hour at 37°C on the walls of polysterene wells in one plate. 
Results and Discussion
Till the end of the second year of this follow-up of 80 hypertensive persons, treated either with ACE inhibitor or with Bblocker according the set-up requirements, the patients were reduced to 61. Their decrease in time, according their sex and treatment type is shown on Fig. 1 .
The executed analysis of reasons for patients' drop off is shown on Table 1 .
Clinical monitoring of hypertensive persons who switched to double anti-hypertensive combination continued, but they were dropped off the tested patients.
Results from treatmnet with ace inhibitors
Changes in AT values in ACE inhibitors treatment According the survey results the AT values in the group treated with ACE inhibitors decrease significantly for the thee indices compared to the values at the beginning and at the end of the second year. ( Table 2) .
Changes in Elastin Degradation
Immunological Indices According the results of the group treated hibitor the EDP quantities diminish significantly.
The anti-elastin antibodies dynamics during the studied period demonstrates intensification of the elastin degradation. Anti-elastin antibodies -IgA, IgG and IgM grow significantly during the second year of treatment compared to the beginning ( Table 4) .
At the end of the first year IgM still grow significantly, and at the end of the second year IgG and IgA do. During the first year IgG anti-elastin antibodies diminish unreliably.
Results from B-blockers treatment
Changes in arterial pressure (AP) values According the survey results AP values in the group treated with B-blockers for the whole treatment period diminish, and after the sixth month of the treatment they significantly diminish, and this tendency remains till the end of the second year compared to the treatment beginning. (Table 5) shment curve characteristic for the SAT does repeat ( Table 6 ).
On Fig. 2 are represented AP changes and EDP changes during the two-years' treat-ment period with B-blocker. It is clearly noticed that all indices' values considerably decrease after six-month treatment with B-blocker. Anti-elastin antibodies after anti-hypertensive therapy with B-blocker. During the two-years' treatment period with Atenolol, the dynamics of anti-elastin antibodies -IgA,IgM and IgG is quite typical ( Table 7 ). In the course of two-years' treatment of arterial hypertension with Bblocker we found out statistically reliable increase of IgG and IgA-antibodies compared to the beginning. In IgM-antibodies was determined significant anti-bodies increase at the end of the first year, and at the end of the second year they decrease to values close to these before the treatment start.
Comparative surveys of elastin degradation in patients treated with atenolol and trandolapril Elastin degradation peptides (EDP) levels in hypertensive patients treated with Bblockers or with ACE-inhibitors
The survey results demonstrate that in the initial hypertensive group (H-initial group) the quantity of elastin-degradation peptides is considerably higher -331±81 ng/ml in comparison to the patients treated for two years with B-blockers (B group) -86.5±38ng/ml. The initial EDP quantity is significantly higher for the group treated with B-blocker -293±13ng/ml. We dis- covered also significantly lower EDP quantity after two-years treatment with ACE-inhibitor (A) -125±38 ng/ml compared to the initial quantity in the whole hypertensive group (H) -331±84 ng/ml and in the group having already treatment with Trandolapril (H ά) -346±21 ng/ml ( Table  8) . Anti-elastin antibodies levels in the tested groups When compared to the initial levels ( Table  9 ) a statistically reliable difference was stated in the quantities of anti-elastin antibodies from different classes in the group treated with B-blocker and in the groups treated with ACE-inhibitor.
IgA -anti-elastin antibodies are more in the hypertensive group before the treatment.
Igm and IgG-anti-elastin antibodies are statistically and reliably higher in both groups -treated with ACE-inhibitors and with B-blockers, compared to the initial group. There is a lineal relation between PAP values and some of the elastin and collagen degradation indices. It is represented in the following graphics. The relation between PAP and IgA-antielastin antibodies in patients who were treated with ACE-inhibitors is strong and reverse: y = 0.673-0.005x; r +0.71; p =0.0001 (Fig. 3) .
The relation between PAT and IgM-antielastin antibodies in patients, treated with ACE-inhibitors is extremely high and reverse:
y=0.8686-0.0063x; r =0.91; p=0.0021 (Fig. 4) .
Strong and reverse is also the regressive relation between PAP and EDP in patients, treated with ACE-inhibitors: y=99.06-17.1x; r=0.72; p=0.0001 (Fig. 5) . There are strong correlation connections between the different indices in the course of the two-years-long treatment with Bblockers. There is a high correlative connection between PAT and IgM-antielastin antibodies in treatment with B-blockers -y=0.818-0.005x; r=0.46; p=0.0056 (Fig. 7) .
Moderate reverse lineal relation is established between PAP and IgG-antielastin antibodies in patients, treated with Bblockers -y=9-0.069x; r=0.4; p=0.046 (Fig. 8) .
In contemporary arterial hypertension treatment the most important criteria is decrease of arterial tension, but the maximum protection of the vessels and other target organs is also very important. Still there are not direct criteria to demonstrate to what degree the medicine treatment has a favourable effect on the vessel wall condition. Some instrumental surveys such as index appraisal -intima /media of aorta carotis or study of byopsy material from glyteal artery are applied in some antihypertensive medicines' perspective surveys.
The results from a study of antihypertensive therapy on vessel wall condition in two widely-used medicines -Atenolol (Bblocker) and Trandolapril (ACE inhibitor) do demonstrate changes in immunological indices. These changes are typical for the elastin degradation and respectively for the vessel wall.
With the ACE-inhibitor Trandolapril was PAP(mm Hg) achieved optimal antihypertensive effect in the tested group. The followed values of arterial tension in the group treated with ACE-inhibitor for the two-years-long survey demonstrate that even at the end of the six month appeared significant SAP,DAP and PAP reduction till normal values; and during the first and second years of the treatment these values keep their level stable (Table 2) .
Influenced by the ACE-inhibitors treatment the elastin peptides quantities decrease gradually (Table 3) . Till the end of the sixth month this decrease is non-significant and only after the first year EDP are significantly decreased compared to the initial quantity.At the end of the second year of this treatment the reduction is ever higher. The delay of elastolytic intensity is slow despite of the good AT control which is applied at the end of the sixth month. The results attained in this survey plainly demonstrate that under medicine control of AP, the EDP being an elastolysis intensity index, do decrease.
Anti-elastin antibodies dynamics demonstrate ( Table 4) that IgM and IgA antibodies levels increase significantly only at the end of the second year. During the first year of treatment they also increase but probably part of them link the persisting fairly big quantities of EDP and due to this we can not find a reliable change.
At the end of the first year of treatment IgG-antibodies demonstrate a certain decrease compared to the initial level; only at the end of the second year they increase significantly. IgG are produced in highest quantity in healthy persons and to the biggest extent are included in the EDP elimination.
At the end of the second year of treatment with ACE-inhibitor, the balance between EDP and antielastin antibodies, which is so typical for healthy persons, is restored; lower EDP quantities with relatively higher antielastin antibodies. Probably under prolonged treatment and AT control, the ACE-inhibitor slows the elastin degradation process.
In the group where the treatment is carried out via B-blocker, the immunological indices changes were also followed.
According the results achieved (Table 5 ), even at the end of the sixth month of the treatment all three parameters for AT -SAP, DAP and PAP, decreased reliably to the norm limits (F>=9.15; p<=0.03). The tendency for decrease in all three parameters is maintained till the end of the first and the second years. Consequently, in the studied group was achieved adequate medicinal control even at the end of the sixth month.
EDP decrease significantly even at the end of the sixth month of treatment with Bblockers and in the next samples taken during the first and the second years their values are close to these of the healthy persons (Table 6 ). From Fig. 2 is seen that when SAP, DAP and PAP values decrease, the elastin degradation peptides' quantity is also reduced. Till the end of the sixth month, the EDP decrease in a steeper manner, and when AT is maintained within the norm limits, the EDP curve is slanter.
While analyzing the changes in antielastin antibodies levels from all types, we establish that at the end of the second year the antibodies from IgA class (F=3.12; p=0.05) do increase reliably despite the Bblocker antihypertensive effect.
IgM-antibodies reach their climax at the end of the first year and then they decrease almost to the levels at the beginning of the treatment. IgG-antielastin atibodies gradually decrease till the end of the first year, and till the end of the second year they increase significantly (F=6.97; p=0.05).
Treatment with adequate B-blocker dosages to keep the arterial tension in normal limits leads to substantial decrease of EDP and anti-elastin antibodies increase. The balance between EDP and anti-elastin antibodies -so typical for healthy persons, is achieved; though the parameters typical for healthy persons are not reached. This is sufficient grounds to claim that B-blockers slow the elastin degradation process, a process so typical for the manifested arterial hypertension.
IgA-antielastin antibodies remain reliably high, they can be interpreted as the sole feature of preceding intensive elastin degradation after two-years-long treatment with B-blocker.
The executed comparative analysis of changes in elastin degradation immunological indices after two-years-long treatment with B-blocker or ACE-inhibitor as monotherapy, and after using the immunological indices initial values for the whole hypertensive group as well as for both sub-groups (Hb and Ha)before the treatment as a base, demonstrate that in the group treated with B-blocker at the end of the second year EDP decrease significantly compared to the beginning; the same is monitored in the group treated with ACEinhibitor. The sufficient arterial tension decrease, despite the medicine applied, leads to elastolic process delay.
The comparative analysis of anti-elastin antibodies levels from the different types under treatment either with B-blocker or ACE-inhibitor, demonstrates that IgA are higher in the group before the treatment, and under the impact of both medicines they decrease significantly after two-yearslong treatment (p=0.005). Under optimal AP control, ACE-inhibitor impacts the IgA levels class -anti-elastin antibodies. This Gopten impact could be a result of its playotrop effects. In both hypertensive groups -under treatment with B-blocker and ACE-inhibitor, was established significant increase of IgG and IgM (p<=0.05).
Despite the applied medicines, the AP control restores the balance between EDP and anti-elastin antibodies.
In the group treated with ACE-inhibitors, the established dependence between PAP and anti-elastin antibodies form the different types demonstrate that PAP has an impact on elastin degradation, but the exact mechanism of this process is still not clarified.
The stated regressive dependencies give us ground to consider that elastin turnover intensity has direct impact on the pulse tension value and consequently on the vessels' damages.
Conclusions
1.After two-years-long antihypertensive therapy with Atenolol or Trandolapril under very good AP control, the elastin turnover was balanced, the intensity of collagen degradation (type I and III) decrease; this is a sign of elasticity and vessel wall protection.
2.The optimal AP control despite the applied medicinal types leads to balance restoration between EDP and antielastin antibodies.
3.The decrease of elastin peptides quantities and IgA-antielastin antibodies' levels to the levels typical for healthy persons can be used as a marker for the protective impact of anti-hypertensive medicines to the vessel wall.
